Mostrar el registro sencillo del ítem

dc.contributor.authorOliva, Gaetano
dc.contributor.authorNieto Martinez, Francisco Javier 
dc.contributor.authorFoglia Manzillo, Valentina
dc.contributor.authorCappiello, Silvia
dc.contributor.authorFiorentino, Eleonora
dc.contributor.authorDi Muccio, Trentina
dc.contributor.authorScalone, Aldo
dc.contributor.authorMoreno, Javier 
dc.contributor.authorChicharro, Carmen 
dc.contributor.authorCarrillo, Eugenia 
dc.contributor.authorButaud, Therese
dc.contributor.authorGuegand, Laurie
dc.contributor.authorMartin, Virginie
dc.contributor.authorCuisinier, Anne-Marie
dc.contributor.authorMcGahie, David
dc.contributor.authorGueguen, Sylvie
dc.contributor.authorCañavate, Carmen 
dc.contributor.authorGradoni, Luigi
dc.date.accessioned2018-12-11T08:55:57Z
dc.date.available2018-12-11T08:55:57Z
dc.date.issued2014-10-09
dc.identifier.citationPLoS Negl Trop Dis. 2014 Oct 9;8(10):e3213es_ES
dc.identifier.issn1935-2735es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6806
dc.description.abstractCanine leishmaniasis is an important zoonosis caused by uncontrolled infection with Leishmania infantum, where an inappropriate immune response is not only responsible for permitting this intracellular parasite to multiply, but is also responsible for several of the pathological processes seen in this disease. Effective canine vaccines are therefore a highly desirable prevention tool. In this randomised, double-blinded, controlled trial, the efficacy of the LiESP/QA-21 vaccine (CaniLeish, Virbac, France) was assessed by exposing 90 naïve dogs to natural L. infantum infection during 2 consecutive transmission seasons, in two highly endemic areas of the Mediterranean basin. Regular PCR, culture, serological and clinical examinations were performed, and the infection/disease status of the dogs was classified at each examination. The vaccine was well-tolerated, and provided a significant reduction in the risk of progressing to uncontrolled active infection (p = 0.025) or symptomatic disease (p = 0.046), with an efficacy of 68.4% and a protection rate of 92.7%. The probability of becoming PCR positive was similar between groups, but the probability of returning to a PCR negative condition was higher in the vaccinated group (p = 0.04). In conclusion, we confirmed the interest of using this vaccine as part of a comprehensive control program for canine leishmaniasis, and validated the use of a protocol based on regular in-depth assessments over time to assess the efficacy of a canine leishmaniasis vaccine.es_ES
dc.description.sponsorshipSeveral of the authors are employees of Virbac, which funded the study. Virbac played a direct role in the study design, data collection and analysis, decision to publish and preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshDog Diseases es_ES
dc.subject.meshDogs es_ES
dc.subject.meshDouble-Blind Method es_ES
dc.subject.meshEndemic Diseases es_ES
dc.subject.meshFemale es_ES
dc.subject.meshInsect Vectors es_ES
dc.subject.meshItaly es_ES
dc.subject.meshLeishmania infantum es_ES
dc.subject.meshLeishmaniasis Vaccines es_ES
dc.subject.meshLeishmaniasis, Visceral es_ES
dc.subject.meshMale es_ES
dc.subject.meshPhlebotomus es_ES
dc.subject.meshSpain es_ES
dc.titleA randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasonses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID25299614es_ES
dc.format.volume8es_ES
dc.format.number10es_ES
dc.format.pagee3213es_ES
dc.identifier.doi10.1371/journal.pntd.0003213es_ES
dc.contributor.funderVirbac (France) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1935-2735es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pntd.0003213es_ES
dc.identifier.journalPLoS neglected tropical diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional